An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread

Completed · Phase 2

Conditions studied: Cancer

In brief

The purpose of this study is to determine whether nivolumab is an effective treatment for cancer that has advanced or has spread. Various tumor types may be eligible for enrollment.

Key facts

Study ID

NCT02832167

Run by

Bristol-Myers Squibb

People needed

239

Starts

2016-02-22

Expected to finish

2021-06-24

Last updated by the study team

2022-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with advanced or metastatic malignancy
• Received standard of care treatment for primary malignancy and standard of care treatment for relapsed cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You may not qualify if…

• Prior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways.
• Subjects previously treated with investigational anticancer therapies less than 6 weeks prior to the first dose of Nivolumab
• Subjects with an active, known, or suspected autoimmune disease
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Arizona Oncology Associates, PC — Tucson, Arizona, United States
• CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• St. Jude Hospital Yorba Linda — Fullerton, California, United States
• LACN — Los Angeles, California, United States
• UCLA Main Campus - University California Los Angeles — Los Angeles, California, United States
• Torrence Health Association, DBA Torrance Memorial;Physician Network/Cancer Care Associates — Redondo Beach, California, United States
• Coastal Integrative Cancer Care — San Luis Obispo, California, United States
• Cancer Center of Santa Barbara with Sansum Clinic — Santa Barbara, California, United States
• Central Coast Medical Oncology Corporation — Santa Maria, California, United States
• Rocky Mountain Cancer Centers - Denver Midtwon — Denver, Colorado, United States
• St. Mary's Hospital And Regional Medical Center — Grand Junction, Colorado, United States
• Memorial Healthcare System — Hollywood, Florida, United States
• Florida Cancer Affiliates — Ocala, Florida, United States
• Orlando Health, Inc — Orlando, Florida, United States
• Florida Cancer Specialists & Research Institute — St. Petersburg, Florida, United States
• Florida Cancer Specialists — West Palm Beach, Florida, United States
• Illinois Cancer Specialists — Niles, Illinois, United States
• Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
• Maryland Oncology Hematology P.A. — Columbia, Maryland, United States
• Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota, United States
• HCA Midwest Healthcare — Kansas City, Missouri, United States
• Oncology Hematology West P.C. dba Nebraska Cancer Specialists — Omaha, Nebraska, United States
• Texas Oncology-Austin Central — Las Vegas, Nevada, United States
• Saint Barnabas Medical Cancer Center — Livingston, New Jersey, United States
• USOR - New York Oncology Hematology, P.C. — Albany, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.